Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review

Duminda Suraweera; Christina Fanous; Melissa Jimenez; Myron J Tong; Sammy Saab

doi:10.14218/JCTH.2017.00064

Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review

J Clin Transl Hepatol. 2018 Jun 28;6(2):119-126. doi: 10.14218/JCTH.2017.00064. Epub 2018 Feb 14.

Authors

Duminda Suraweera¹, Christina Fanous², Melissa Jimenez², Myron J Tong³, Sammy Saab^{2

4}

Affiliations

¹ Department of Medicine, Olive-View Medical Center, Sylmar, CA, USA.
² Department of Surgery at the University of California at Los Angeles, Los Angeles, CA, USA.
³ Huntington Research Institute, Pasadena, CA, USA.
⁴ Department of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA.

Abstract

Background and Aims: Hypercholesterolemia is a common finding in patients with primary biliary cholangitis (PBC) and is a well-defined risk factor for cardiovascular disease. However, studies have been mixed on whether PBC patients do, in fact, have higher cardiovascular risk. The aim of this study is to review the current literature and provide an evidence-based assessment of cardiovascular risk in PBC patients. Methods: We performed a systematic literature search on PubMed regarding patients with PBC and cardiovascular events from the database inception to July 1, 2017. A total of 33 articles fulfilling our inclusion criteria were found. Results: The majority of the studies evaluated yielded no statistically significant difference in cardiovascular disease in the PBC population compared to the general public. However, some reports found a statistically significantly increase in coronary artery disease. Several studies have looked at the specific lipid profile of patients with PBC with hypocholesteremia. While these lipid abnormalities differ by stage of disease, there is evidence to suggest that the specific lipid profile in PBC may have lower atherogenicity than in patients with hypercholesterolemia without PBC. Studies looking at patients with PBC with other risk factors for cardiovascular disease, such as hypertension and metabolic syndrome, have consistently found a higher risk for cardiovascular disease in these patients. Statin treatment is effective in reducing lipid levels and possibly improving endothelial inflammation in patients with PBC with hypercholesterolemia. Conclusions: There is not enough evidence to suggest an increased risk of cardiovascular disease in patients with PBC with hypercholesterolemia, except for those individuals with concomitant features of metabolic syndrome. In patients with PBC with no additional cardiovascular risk factors, individual risk/benefit discussion on lipid-lowering treatment should be considered.

Keywords: Cardiovascular risk; Hypercholesterolemia; Primary biliary cholangitis (PBC).